Returning guest, Dr. Brad Marder a nephrologist for nearly 20 years and now Medical Director of Nephrology at Horizon Therapeutics discusses findings from the Renal Data System study, on which he was an author, and how KRYSTEXXA (pegloticase) is applied in real-world care for people who receive dialysis for advanced kidney disease. These data were presented at the American Society of Nephrology (ASN) 2020, Abstract PO1166 titled “A USRDS Database Study on the Use of Pegloticase in Patients Undergoing Dialysis”
Brad Marder M.D. is the medical director of nephrology in medical affairs at Horizon Therapeutics, a global pharmaceutical company focused on creating treatments for rare and rheumatic conditions.
Dr. Marder has devoted his career to both patient care and groundbreaking research. Since completing a nephrology fellowship at Icahn School of Medicine at Mount Sinai in New York City, he has served as the director of clinical research and the principal investigator in multiple clinical trials on treatments for kidney transplant patients and those with chronic kidney disease. He has authored numerous publications dedicated to bringing innovative therapies to patients in need.
Prior to joining the leadership ranks at Horizon, Dr. Marder worked as a transplant physician and medical director for Presbyterian/St. Luke’s Transplant Center and as chairman of the department of medicine for Presbyterian/St. Luke’s Medical Center in Denver. He has served in multiple hospital committees and as an advisor for Donor Alliance, Colorado’s organ procurement organization.
A native of California, Dr. Marder earned his bachelor’s degree in molecular biology from the University of California, Berkeley, and his doctor of medicine from the Sackler School of Medicine at Tel Aviv University, after which he completed an internship and residency in internal medicine at the Montefiore Medical Center of the Albert Einstein College of Medicine in New York.